
Stapokibart: A New Hope for Patients with Severe Chronic Rhinosinusitis with Nasal Polyps
Stapokibart, a novel IL-4Rα monoclonal antibody, significantly reduced polyp size, nasal congestion, and improved smell and quality of life in patients with severe chronic rhinosinusitis with nasal polyps, according to the CROWNS-2 phase 3 trial published in JAMA.
Read more


























Most Commented